<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445650</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-SLS-006</org_study_id>
    <nct_id>NCT03445650</nct_id>
  </id_info>
  <brief_title>RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the&#xD;
      Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson&#xD;
      Syndrome (SLS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">January 18, 2020</completion_date>
  <primary_completion_date type="Actual">January 18, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Index Ichthyosis Severity (VIIS) Scaling severity score as assessed by the investigator.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Severity of scaling based on the VIIS score system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(VIIS) Erythema severity score.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Severity of erythema based on the VIIS score system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Area under the curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Maximum Plasma Concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Time to Maximum Plasma Concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Transepidermal water loss.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Sjogren-Larsson Syndrome</condition>
  <arm_group>
    <arm_group_label>ADX-102 1% Topical Dermal Cream (reproxalap)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of ADX-102 Topical Dermal Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 1% Topical Dermal Cream (reproxalap)</intervention_name>
    <description>ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months in Part 1 and Part 2.</description>
    <arm_group_label>ADX-102 1% Topical Dermal Cream (reproxalap)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of ADX-102 Topical Dermal Cream</intervention_name>
    <description>Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months in Part 1 and Part 2.</description>
    <arm_group_label>Vehicle of ADX-102 Topical Dermal Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is aged 3 years or older&#xD;
&#xD;
          -  Subject has a genetically-confirmed diagnosis of SLS.&#xD;
&#xD;
          -  Subject has active ichthyosis that is Grade 2 or higher on the VIIS scaling severity&#xD;
             score.&#xD;
&#xD;
          -  Females of child-bearing potential: Negative pregnancy test at Screening and Baseline&#xD;
             Visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has evidence of a serious active infection.&#xD;
&#xD;
          -  Systemic or topical retinoids or other topical medications, not including emollients,&#xD;
             within the past 30 days Baseline Visit 1.&#xD;
&#xD;
          -  Subject has received an investigational systemic or topically administered drug within&#xD;
             the past 30 days prior to Baseline Visit 1.&#xD;
&#xD;
          -  Subject is currently receiving immunosuppressive therapy, including intermittent or&#xD;
             low-dose systemic corticosteroids.&#xD;
&#xD;
          -  Subject has a known allergic reaction to any ingredients of study drug formulation.&#xD;
&#xD;
          -  Subject has any clinically significant laboratory test abnormalities or a history of&#xD;
             any other condition that, in the opinion of the Investigator, could compromise the&#xD;
             subject's ability to comply with the protocol or that could compromise the subject's&#xD;
             safety or the interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADX-102, Sjögren-Larsson Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Sjogren-Larsson Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

